CANTON, Conn., May 18, 2023 — Kelyniam Global (OTC: KLYG), a leading maker of custom cranial implants, today announced results for its quarter ended March 31, 2023. “I’m pleased to announce that Kelyniam has expanded our licensing agreement with Bioplate to allow the Company to sell Osteopore products in select markets in the U.S. Kelyniam...Read More

Kelyniam Global (OTC: KLYG), a maker of custom cranial implants, today announced results for its year ended December 31, 2022. The complete financials are available here. “2022 was the sixth year in a row that Kelyniam has meaningfully increased sales while successfully competing against much larger competitors” said Ross Bjella, Kelyniam’s CEO. “Neurosurgeons rely on...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended September 30, 2022. “Revenues in Q3 were significantly ahead of last year and we expect continued strong sales performance through the end of the year”, said Ross Bjella, Kelyniam’s Chairman and CEO. “The quarter over quarter...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended June 30, 2022. “Our strong sales performance in Q2 resulted in 20% growth over the same period last year, and 10% growth over the previous quarter. Sales from Finceramica’s CustomizedBone implant contributed to this performance and...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended March 31, 2021. “Revenue and profitability in Q1 were essentially flat as compared to the previous year,” said Ross Bjella, Kelyniam’s Chairman and CEO. “2021 Q1 revenue was artificially high due to pent up Covid related...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its year ended December 31, 2021. “The company is excited to report that sales have increased for the fifth year in a row,” said Ross Bjella, Kelyniam’s CEO. “Despite Covid 2.0 shutdowns during the 1st quarter of 2021 and...Read More

European market leading implant now available in the U.S. COLLINSVILLE, CT., December 23, 2021 — Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial PEEK implants today announced that it has entered into a strategic licensing agreement with Fin-ceramica faenza spa to market the company’s hydroxyapatite patient specific implant. This bio-mimetic ceramic biomaterial...Read More

Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its third quarter ended September 30, 2021. “Strong quarterly sales growth in Q3 made up for delayed procedures due to the Covid 19 Delta variant that affected scheduling in Q2, resulting in YTD sales being approximately flat to the same period last...Read More

CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its half year ended June 30, 2021. “Period comparisons for 2021 and 2020 are very difficult to evaluate due to the multiple effects of the Covid 19 pandemic in 2020. The second quarter of 2020 results were uniquely affected...Read More

CANTON, CT >> Kelyniam Global (KLYG), a maker of custom cranial implants, has released its financial results for the three months ended March 31, 2021 showing profitability despite pandemic related challenges. The Corporations Q1 financial statements are available here. Ross Bjella, Chairman and CEO said, “Despite the uptick in the second surge of Covid infections...Read More